BLFS Stock Overview
Develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
BioLife Solutions, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.60 |
| 52 Week High | US$27.36 |
| 52 Week Low | US$9.92 |
| Beta | 1.87 |
| 11 Month Change | 11.06% |
| 3 Month Change | 16.97% |
| 1 Year Change | 129.11% |
| 33 Year Change | -46.38% |
| 5 Year Change | 82.32% |
| Change since IPO | -95.10% |
Recent News & Updates
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Oct 25
Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Sep 14Recent updates
Is BioLife Solutions (NASDAQ:BLFS) Using Debt Sensibly?
Oct 25Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Sep 14Why BioLife Solutions, Inc. (NASDAQ:BLFS) Could Be Worth Watching
Aug 30Investors Appear Satisfied With BioLife Solutions, Inc.'s (NASDAQ:BLFS) Prospects As Shares Rocket 28%
Aug 14BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Jun 20A Look At The Fair Value Of BioLife Solutions, Inc. (NASDAQ:BLFS)
Jun 05Revenues Not Telling The Story For BioLife Solutions, Inc. (NASDAQ:BLFS) After Shares Rise 25%
May 14Broker Revenue Forecasts For BioLife Solutions, Inc. (NASDAQ:BLFS) Are Surging Higher
May 13Should You Investigate BioLife Solutions, Inc. (NASDAQ:BLFS) At US$19.54?
May 11Does BioLife Solutions (NASDAQ:BLFS) Have A Healthy Balance Sheet?
Mar 12BioLife Solutions, Inc.'s (NASDAQ:BLFS) Intrinsic Value Is Potentially 64% Above Its Share Price
Feb 19BioLife Solutions, Inc.'s (NASDAQ:BLFS) Share Price Matching Investor Opinion
Dec 19Downgrade: Here's How Analysts See BioLife Solutions, Inc. (NASDAQ:BLFS) Performing In The Near Term
Aug 17Is BioLife Solutions (NASDAQ:BLFS) Weighed On By Its Debt Load?
Aug 11Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
May 06Should You Think About Buying BioLife Solutions, Inc. (NASDAQ:BLFS) Now?
Feb 22Health Check: How Prudently Does BioLife Solutions (NASDAQ:BLFS) Use Debt?
Jan 10Is There An Opportunity With BioLife Solutions, Inc.'s (NASDAQ:BLFS) 20% Undervaluation?
Dec 10BioLife: What The Future Holds
Oct 19BioLife Solutions COO Roderick de Greef to retire
Oct 03BioLife Solutions (NASDAQ:BLFS) Has Debt But No Earnings; Should You Worry?
Sep 27Shareholder Returns
| BLFS | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 10.6% | 3.7% | -0.8% |
| 1Y | 129.1% | 18.9% | 31.5% |
Return vs Industry: BLFS exceeded the US Life Sciences industry which returned 18.9% over the past year.
Return vs Market: BLFS exceeded the US Market which returned 31.5% over the past year.
Price Volatility
| BLFS volatility | |
|---|---|
| BLFS Average Weekly Movement | 7.3% |
| Life Sciences Industry Average Movement | 7.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BLFS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BLFS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 412 | Rod de Greef | www.biolifesolutions.com |
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line that comprises of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
BioLife Solutions, Inc. Fundamentals Summary
| BLFS fundamental statistics | |
|---|---|
| Market cap | US$1.20b |
| Earnings (TTM) | -US$63.55m |
| Revenue (TTM) | US$139.96m |
8.8x
P/S Ratio-19.3x
P/E RatioIs BLFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLFS income statement (TTM) | |
|---|---|
| Revenue | US$139.96m |
| Cost of Revenue | US$89.11m |
| Gross Profit | US$50.85m |
| Other Expenses | US$114.40m |
| Earnings | -US$63.55m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | -1.38 |
| Gross Margin | 36.33% |
| Net Profit Margin | -45.40% |
| Debt/Equity Ratio | 6.6% |
How did BLFS perform over the long term?
See historical performance and comparison